Chimerix (CMRX) : The highest short term price target forecast on Chimerix (CMRX) is $12 and the lowest target price is $5. A total of 7 equity analysts are currently covering the company. The average price of all the analysts is $7.29 with a standard deviation of $2.29.
Chimerix (CMRX) : 1 brokerage houses believe that Chimerix (CMRX) is a Strong Buy at current levels. 6 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Chimerix (CMRX). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 8 Wall Street Analysts endorse the stock as a Hold with a rating of 2.91.
Chimerix (NASDAQ:CMRX): The stock opened at $4.87 on Thursday but the bulls could not build on the opening and the stock topped out at $4.91 for the day. The stock traded down to $4.59 during the day, due to lack of any buying support eventually closed down at $4.62 with a loss of -3.95% for the day. The stock had closed at $4.81 on the previous day. The total traded volume was 481,353 shares.
Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).